Company
Every published round Takeda took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Takeda has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for Takeda, as distinct from the investments it has made.
Companies Takeda has backed that another company then bought. An exit for the holding, not a deal Takeda did.
| Company | Bought by | Kind | Announced | Price |
|---|---|---|---|---|
| No portfolio company of Takeda is recorded as having been acquired. | ||||
Companies Takeda acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Company | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| Shire | Acquisition | 2018 | - | Brandon BioCatalyst, Brandon Capital |
Stories naming Takeda. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech Certa Therapeutics has acquired OccuRx, combining two GPR68 fibrosis pipelines founded by Professor Darren Kelly, and says it will seek Series B funding to advance clinical development.